Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.
Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.
复制标题
DOI：
10.1016/j.eclinm.2021.101018
复制
发表时间：
2021-08
影响因子：
15.1
通讯作者：
McDade TW
中科院分区：
文献类型：
--
作者：
Demonbreun AR;Sancilio A;Velez MP;Ryan DT;Saber R;Vaught LA;Reiser NL;Hsieh RR;D'Aquila RT;Mustanski B;McNally EM;McDade TW
最近的报告表明，在以前感染过SARS-CoV-2的个体中，单次mRNA疫苗剂量足以引发高水平的免疫力。通过血清状态和急性病毒诊断史比较非住院参与者接种疫苗后抗sars - cov -2刺突受体结合域（RBD） IgG抗体浓度和抗体介导的刺突血管紧张素转换酶（ACE2）受体结合的中和。在芝加哥地区（美国）以社区为基础、家庭收集的纵向血清调查中，对参与者接种mRNA疫苗（BNT162b2/辉瑞或mRNA-1273/Moderna）前后进行分析；没有人报告因COVID-19住院。样本于2021年1月和2月采集。在接种疫苗前，一些人报告急性病毒诊断检测呈阳性，血清呈阳性（COVID-19+）；其他未报告急性病毒诊断检测的患者根据抗刺突RBD IgG检测结果分为血清阳性或血清阴性。在307名独特疫苗接种者中，46人报告了先前的COVID-19诊断并且血清阳性（COVID-19 +）。在261名无急性病毒诊断检测史的儿童中，接种疫苗前血清阳性117人，血清阴性144人。中位年龄为38岁（21 ~ 83岁），其中女性67例，男性33%；40%是非白人。在一次（n = 142）或两次（n = 191）剂BNT162b2或mRNA-1273疫苗后评估反应。1剂后，COVID-19+组（中位48.2µg/ml, IgG，中和率为99.9%）的疫苗后IgG浓度和替代中和率均显著高于血清阳性组（3.6µg/ml IgG，中和率为56.5%）和血清阴性组（2.6µg/ml IgG，中和率为38.3%）。后两组在第二次接种后达到95%的中和。在接种一剂mRNA疫苗后，先前诊断为COVID-19的个体表现出高水平的抗rbd IgG和替代中和的spike-ACE2相互作用。在大多数没有临床COVID-19诊断的SARS-CoV-2感染者中，一剂mRNA疫苗不足以产生比较高的反应，在血清阴性人群中也是如此。美国国家科学基金2035114，美国国立卫生研究院3UL1TR001422-06S4，西北大学研究办公室。
Recent reports have suggested that among individuals previously infected with SARS-CoV-2, a single mRNA vaccine dose is sufficient to elicit high levels of immunity. We compared anti-SARS-CoV-2 spike receptor binding domain (RBD) IgG antibody concentrations and antibody-mediated neutralization of spike-angiotensin-converting enzyme (ACE2) receptor binding in vitro following vaccination of non-hospitalized participants by sero-status and acute virus diagnosis history. Participants were analysed before and after mRNA vaccination (BNT162b2/Pfizer or mRNA-1273/Moderna) in a community-based, home-collected, longitudinal serosurvey in the Chicago area (USA); none reported hospitalization for COVID-19. Samples were collected in January and February 2021. Before vaccination, some reported prior positive acute viral diagnostic testing and were seropositive (COVID-19+); the others who did not report acute viral diagnostic testing were categorized as seropositive or seronegative based on anti-spike RBD IgG test results. Of 307 unique vaccine recipients, 46 reported a prior COVID-19 diagnosis and were seropositive (COVID-19 +). Of the 261 with no history of acute viral diagnostic testing, 117 were seropositive and 144 seronegative before vaccination. The median age was 38 years (range 21–83) with 67 female and 33% male; 40% were non-White. Responses were evaluated after one (n = 142) or two (n = 191) doses of BNT162b2 or mRNA-1273 vaccine. After one dose, median post-vaccine IgG concentration and percent surrogate neutralization were each significantly higher among the COVID-19+ (median 48·2 µg/ml, IgG; > 99.9% neutralization) compared to the seropositives (3·6 µg /ml IgG; 56.5% neutralization) and seronegatives (2·6 µg /ml IgG; 38·3% neutralization). The latter two groups reached > 95% neutralization after the second vaccine dose. After one dose of mRNA vaccine, individuals previously diagnosed with COVID-19 responded with high levels of anti-RBD IgG and surrogate neutralization of spike-ACE2 interaction. One dose of mRNA vaccine was not sufficient to generate comparably high responses among most persons previously infected with SARS-CoV-2 without a clinical COVID-19 diagnosis, nor among seronegative persons. National Science Foundation 2035114, NIH 3UL1TR001422–06S4, and Northwestern University Office of Research.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
8
作者：
Abe, Kento T.;Li, Zhijie;Gingras, Anne-Claude
通讯作者：
Gingras, Anne-Claude
影响因子：
4.2
作者：
Mei, JV;Alexander, JR;Hannon, WH
通讯作者：
Hannon, WH
影响因子：
82.9
作者：
Amanat F;Stadlbauer D;Strohmeier S;Nguyen THO;Chromikova V;McMahon M;Jiang K;Arunkumar GA;Jurczyszak D;Polanco J;Bermudez-Gonzalez M;Kleiner G;Aydillo T;Miorin L;Fierer DS;Lugo LA;Kojic EM;Stoever J;Liu STH;Cunningham-Rundles C;Felgner PL;Moran T;García-Sastre A;Caplivski D;Cheng AC;Kedzierska K;Vapalahti O;Hepojoki JM;Simon V;Krammer F
通讯作者：
Krammer F
DOI：
10.1056/nejmoa2034545
发表时间：
2021-02-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
Lumley SF;O'Donnell D;Stoesser NE;Matthews PC;Howarth A;Hatch SB;Marsden BD;Cox S;James T;Warren F;Peck LJ;Ritter TG;de Toledo Z;Warren L;Axten D;Cornall RJ;Jones EY;Stuart DI;Screaton G;Ebner D;Hoosdally S;Chand M;Crook DW;O'Donnell AM;Conlon CP;Pouwels KB;Walker AS;Peto TEA;Hopkins S;Walker TM;Jeffery K;Eyre DW;Oxford University Hospitals Staff Testing Group
通讯作者：
Oxford University Hospitals Staff Testing Group